Parvus Therapeutics has announced an agreement with National Resilience for the tech transfer, scale-up and GMP manufacturing of PVT-201, Parvus' lead Navacim drug candidate being developed to treat primary biliary cholangitis.

EPV-CoV-19 vaccine sequences are 98% conserved in SARS-CoV-2 Omicron variant

Biomica reports on BMC-333 in DSS-induced colitis model

Today's news in brief

BioWorld

BioWorld briefs for April 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Grace Therapeutics hits CRL setback with GTx-104 despite positive trial

BioWorld

Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...

Epileptic brain and abnormal EEG wave discharges

Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest

BioWorld

A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...

Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal

BioWorld

The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...